Juvenescence closes a $76M first tranche of its Series B-1, led by Abu Dhabi's M42

Juvenescence

Juvenescence secured $76M in the first close of a Series B-1 led by M42 alongside existing investors, with a second close expected in Q3 2025. The funding enables advancement of its therapeutic portfolio into clinical development and will establish a drug discovery hub in Abu Dhabi leveraging M42's clinical trial infrastructure and genomics capabilities.

• $76M first tranche led by M42 with existing investors; second close expected Q3 2025.
• Partnership establishes drug development hub in Abu Dhabi using M42's biobanking and clinical trial infrastructure.
• M42 Omics Center of Excellence and Abu Dhabi Biobank (900,000+ samples) support research in cognition, cardio-metabolism, immunity, and cellular repair.